-+ 0.00%
-+ 0.00%
-+ 0.00%

Zentalis doses first patient in Phase 3 ASPENOVA trial for platinum-resistant ovarian cancer

PUBT·05/05/2026 12:04:17
Listen to the news
Zentalis doses first patient in Phase 3 ASPENOVA trial for platinum-resistant ovarian cancer
  • Zentalis Pharmaceuticals dosed first patient in ASPENOVA, global Phase 3 trial testing WEE1 inhibitor azenosertib versus standard-of-care chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer.
  • Clinical results have not been reported from ASPENOVA; DENALI Phase 2 topline results are expected by year-end 2026, with prior activity discussed at SGO Annual Meeting 2025.
  • Program aims to support accelerated approval via DENALI, with ASPENOVA positioned as confirmatory study for conversion to full approval, pending FDA feedback.
  • Trial strategy targets a biomarker-defined subgroup linked to poor outcomes, seeking to show azenosertib can outperform existing chemotherapy options without relying on intravenous treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050800PRIMZONEFULLFEED9712952) on May 05, 2026, and is solely responsible for the information contained therein.